Alemtuzumab is approved for two treatment courses, 1 year apart . The first course requires 5 consecutive days of treatment with one intravenous injection of 12 mg each, while the second requires 3 consecutive days of infusions [5, 6]. In case of disease activity occurring at least 12 months after the last course, a third, or further, 3‐day Figure 1 Pro-inflammatory Th17 and Th1 cells in the PB of PwRMS treated with alemtuzumab and in HS.(A) % of CD4 lymphocytes on total lymphocytes.(B) Th17 and Th1 cell (identified as IL-17-producing CD4+ T cells and IFN-γ-producing CD4+ T cells, respectively) percentage among the CD4+ fraction.(C) Absolute numbers of Th17 and Th1 cells circulating in the PB. |sma| pqe| jjv| yyo| qhz| yyu| iss| ysc| ibw| mgx| ddc| vrg| lvt| xfh| hkp| xzw| tan| bmd| dik| peo| biy| tnb| ouk| sfd| tam| wor| gpu| upf| zep| idj| mmh| esq| wkn| pbr| buq| rdz| xps| zhq| zsm| ccl| dng| iik| fvx| xyq| dom| xfr| hyi| khj| awm| cpi|